Related Experiment Video

Updated: Jul 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future

Qi-Dong Xia1, Si-Han Zhang1, Na Zeng1

  • 1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|November 5, 2023
PubMed

Insights

Novel androgen receptor inhibitors (ARi) are now standard for metastatic hormone-sensitive prostate cancer (mHSPC), offering improved survival. This review details ARi properties and clinical trial data to guide first-line treatment choices.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Androgen receptor (AR) signaling is crucial in prostate cancer progression.
  • Traditional androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) often leads to resistance.
  • Emerging novel AR inhibitors (ARi) represent a significant advancement in mHSPC treatment.

Purpose of the Study:

  • To provide a comprehensive overview of novel AR inhibitors for mHSPC.
  • To analyze molecular structure, pharmaceutical properties, efficacy, and safety data from pivotal trials.
  • To guide clinical decision-making for first-line mHSPC treatment strategies.

Main Methods:

  • Systematic review of pivotal clinical trials involving novel AR inhibitors in mHSPC.
  • Analysis of molecular structure and pharmaceutical properties of studied AR inhibitors.
  • Evaluation of efficacy and safety data, including disease progression and overall survival.

Main Results:

  • Novel AR inhibitors demonstrate substantial benefits in delaying disease progression and prolonging survival in mHSPC.
  • These agents have become the new standard of care, offering improved outcomes compared to ADT alone.
  • Pivotal trials confirm the efficacy and safety profiles of various novel AR inhibitors.

Conclusions:

  • Novel AR inhibitors have transformed the first-line treatment landscape for mHSPC.
  • Understanding the differences in ARi development and application is essential for optimizing treatment selection.
  • Ongoing research and Phase III trials will further refine the role of ARi in advanced prostate cancer management.
Keywords:
Androgen deprivation therapyMetastatic hormone-sensitive prostate cancerNovel androgen receptor inhibitorsTreatment choice

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
869
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
891
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K